Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
25.08
-0.61 (-2.37%)
Nov 17, 2026, 3:00 PM CST

SHA:688319 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
792.14700.13586.1494.29546.68485.29
Other Revenue
4.034.032.751.830.81.86
796.18704.16588.86496.12547.48487.15
Revenue Growth
12.28%19.58%18.69%-9.38%12.38%52.18%
Cost of Revenue
74.8963.1729.7736.7343.0128.36
Gross Profit
721.29641559.09459.39504.48458.79
Selling, General & Admin
528.72456.1389.32336.12352.06296.33
Research & Development
107.8132.9134.23114.73121.9956.36
Other Operating Expenses
8.656.053.723.323.553.21
Operating Expenses
642.24608.26537.47455.89489.78364.9
Operating Income
79.0432.7321.623.5114.793.89
Interest Expense
-4.17-14.99-14.46-7.18-5.07-1.23
Interest & Investment Income
0.421.15.363.67.555.19
Currency Exchange Gain (Loss)
-0.01-0.01----
Other Non Operating Income (Expenses)
-60.610.09-0.250.07-0.21-0.19
EBT Excluding Unusual Items
14.6718.9212.28-0.0116.9797.67
Gain (Loss) on Sale of Assets
-0.410.01-0.03-0.15-0.15-0.05
Asset Writedown
4.08-----
Other Unusual Items
11.9312.9610.0615.7726.839.57
Pretax Income
30.2731.8922.315.6243.65107.19
Income Tax Expense
62.339.996.584.1817.07-0.77
Earnings From Continuing Operations
-32.0621.915.7211.4426.58107.96
Minority Interest in Earnings
0.040.365.046.11--
Net Income
-32.0222.2620.7617.5626.58107.96
Net Income to Common
-32.0222.2620.7617.5626.58107.96
Net Income Growth
-7.24%18.24%-33.95%-75.38%198.82%
Shares Outstanding (Basic)
405405405405405385
Shares Outstanding (Diluted)
405405405405405385
Shares Change
0.12%0.01%-0.01%0.07%5.22%5.61%
EPS (Basic)
-0.080.050.050.040.070.28
EPS (Diluted)
-0.080.050.050.040.070.28
EPS Growth
-7.23%18.25%-33.99%-76.61%182.95%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-106.76.68-217.05-125.88-225.24-29.75
Free Cash Flow Per Share
-0.260.02-0.54-0.31-0.56-0.08
Dividend Per Share
---0.038--
Dividend Growth
------
Gross Margin
90.59%91.03%94.94%92.60%92.14%94.18%
Operating Margin
9.93%4.65%3.67%0.71%2.69%19.27%
Profit Margin
-4.02%3.16%3.52%3.54%4.85%22.16%
Free Cash Flow Margin
-13.40%0.95%-36.86%-25.37%-41.14%-6.11%
EBITDA
116.0466.250.430.6240116.93
EBITDA Margin
14.57%9.40%8.56%6.17%7.31%24.00%
D&A For EBITDA
36.9933.4728.7827.1125.323.04
EBIT
79.0432.7321.623.5114.793.89
EBIT Margin
9.93%4.65%3.67%0.71%2.69%19.27%
Effective Tax Rate
205.92%31.34%29.52%26.74%39.11%-
Revenue as Reported
197.24704.16588.86496.12547.48487.15
Advertising Expenses
-331.88264.73224.9248.75212.96